Stem Cell Market

Global Stem Cell Market Size (2022 to 2027)

As per our report, the global stem cell market size is estimated to be worth USD 29028 million by 2027 and USD 16166 million in 2022, growing at a CAGR of 12.42% during the forecast period. The market is to increase because of the extensive research and development, which is gaining significant importance.

In multicellular organisms, stem cells have a unique ability to regenerate into a specific cell to form different tissues in the body. These cells can work as a replacement in place of damaged tissue cells and have full applications in healthcare. As a result, it has been accepted throughout the world.

Regenerative medicine is possibly the most important use of stem cells, and other essential areas comprise cardiology, neurology, orthopedics, hematology, and oncology. Another widely used application is drug discovery and growth. Stem cells are a research tool because in vitro study would allow scientists to deeply understand the role of various organs and the development of diseases. Stem cell therapy has shown significant potential to treat cancer successfully.

Impact of COVID-19 on the global stem cell market:

The novel coronavirus (COVID 19) appeared at the start of 2020 with quick spread worldwide. The COVID 19 cases are rising rapidly, affecting millions of people and business sectors, including the healthcare field. The pandemic has been challenging for centers undertaking autologous hematopoietic stem cell transplants (HSCT). The primary threat in HSCT is infection exposure. The clinical reviews contemplated how the delivery of HSCT services should be governed for patients and donors amid the pandemic crisis and how to reduce COVID 19 at all the stages of stem cell transplants. In the present status of the COVID 19 pandemic spreading across the globe, stem cell transplant specialists need to schedule a thorny path further with sudden challenges. Medical professionals are trying to avoid transplant recipients and their respective donors in stem cell transplant programs worldwide, so hematopoietic stem cell transplant needs to be conducted easily and risk-free. 

MARKET DRIVERS:

The rising adoption of stem cells in cancer treatment is the primary factor driving global stem cell market growth.

According to WHO, cancer is the second leading cause of death globally; it is estimated that around 9.6 million deaths in 2018. The research will treat cancer using stem cells to fuel the growth of the stem cell market. For Instance, somatic stem cell therapy or bone marrow transplant is a procedure used to treat leukemia (blood cancer) as bone marrow has many stem cells.

Growing research activities using stem cells to develop new therapies to expand treatment options for various diseases and increase the adoption of these cells to replace the damaged tissue cells propels the global stem cell market growth. For Instance, the umbilical cord is to be discarded as a by-product of the birth process, but it was found that the blood in the umbilical cord is stem cell-rich and can be used to treat different 80 diseases in the human body.

New stem cell banks are coming up to fulfill the increasing demand for stem cell storage. Thus, the entry of new players is anticipated to boost the market's need. Different cell lines are used to develop a vaccine against infection. The increasing awareness about the use of stem cells is further propelling the market growth. 

MARKET RESTRAINTS:

The most significant restraints of the stem cell market are the cost required for the storage and maintenance of the stem cell is comparatively more. The research needs a lot of funding, and a small error can cost a lot. Furthermore, it requires a skilled workforce which is very hard to get in this competitive market. Additionally, the controversy regarding the ethics in the research and the complexities related to the stem cell procedure affect the market growth.

Europe is known for its exceptional research quality and strength of product pipelines. Japan was one of the pioneers in the field of iPS research. HEALIOS K.K., a Japanese-based pharmaceutical company, is one of the first companies to test iPS treatment in the country. The company plans to market its product by 2022. Such initiatives are boosting the Jarevenue generation in the region.

The improved quality of differentiated cells due to efficient manufacturing due to the collaborations is likely to expand growth opportunities for the stem cell market. In addition, the market to receive growth opportunities by integrating different fields like materials, devices, chemical compounds, and biologics during the forecast period.

REPORT COVERAGE:

This research report on the global stem cell market has been segmented and sub-segmented based on treatment mode, cell type, technology segment, and region.

Stem Cell Market - By Treatment Mode:

• Allogeneic
• Autologous Stem Cell Therapy

Based on treatment mode, allogeneic therapy is estimated to occupy most of the global stem cell market share during the forecast period. The allogeneic cell can produce its immune cell, which inhibits the growth of the cancer cell. It is used to stop the reoccurrence of cancer.

Besides, autologous stem cell therapy is also predicted to see promising growth in the coming years. It is used for the treatment of people to treat damaged bone marrow.

Stem Cell Market - By Cell Type:

• Adult Stem Cells
• Induced Pluripotent Stem Cells
• Human Embryonic Stem Cells
• Others

Based on the cell type, the segment is dominated by the adult stem cell segment as they are used to treat cancer. The induced pluripotent stem has the second largest market share; it is used in research to discover premature aging, congenital heart disease, and cancer. Regenerative medicine is also a growing segment for treating Alzheimer's and Parkinson's. The human embryonic stem cell segment is also growing as the number of cord cell preservation is increasing.

Stem Cell Market - By Technology:

• Cell Acquisition
• Cell Production
• Cryopreservation
• Other Sub-Segments

Based on technology, the cell acquisition segment has acquired the largest share of the global stem cell market in the recent past. The cell acquisition technique extracts bone marrow stem cells and replaces bone marrow.

Stem Cell Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American stem cell market is currently dominating the global market. This region maintains the trend due to increasing awareness about the therapeutic potential of stem cells, increasing funds for research, and improving several clinical trials for stem-cell-based products. 

The European stem cell market accounted for a substantial share of the global market in 2021 and was worth USD 3305 million in 2021.

However, the Asia-Pacific stem cell market is expected to rise at a significant CAGR during the forecast period, mainly because of better regulatory support by encouraging government policies and increasing awareness among the public. APAC Stem Cell Market to have decent growth opportunities with the rising incidences of infection. Also, the development of vaccines using various human diploid and non-tumorigenic cell lines is to escalate the market demand. In addition, ongoing research and development of different disease vaccines are expected to drive market growth during the forecast period.

The Latin American stem cell market is predicted to grow at a CAGR of 10.9% from 2022 to 2027.

The stem cell market in the Middle East and Africa is forecasted to be worth USD 2852 million by 2027.

KEY MARKET PARTICIPANTS:

Some of the notable companies that are profiled in the global stem cell market are Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc.

RECENT MARKET DEVELOPMENTS:

• Research on mesenchymal stem cells was carried out in 2019 by the research professionals at the University of Freiberg.
• Mesoblast Company collaborates with Grunenthal Inc. to develop innovative cell therapy for treating chronic low back pain. Grunanthal acquired rights from Mesoblast to commercialize MPC-06-ID in Latin America and Europe.